Podiatrists in Yarmouth, ME Accepting Medicare

2 Podiatrists found. Showing 1 - 2

Dr. Barry M White, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 45 Forest Falls Dr, Yarmouth, ME 04096 Phone: 207-888-3640    Fax: 207-847-3000

Coastal Maine Foot And Ankle Pa Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 45 Forest Falls Dr, Yarmouth, ME 04096 Phone: 207-751-3970

News Archive

Study shows prevalence of PTSD responses in female patients after cancer treatment

A paper published in the current issue of psychotherapy and psychosomatics provides data concerned with the appropriateness of a diagnosis of post-traumatic stress disorder in women with a diagnosis of cancer.

Scientists compare neuronal network connections in 2 worm species

Researchers in the group of Ralf Sommer at the Max Planck Institute for Developmental Biology in Tuebingen, Germany, have for the first time been able to identify neuronal correlates of behaviour by comparing maps of synaptic connectivity, or "connectomes", between two species with different behaviour.

Differences in regional readmission rates for heart failure tied to socioeconomics, availability of care

Differences in regional hospital readmission rates for heart failure are more closely tied to the availability of care and socioeconomics than to hospital performance or patients' degree of illness, according to research presented at the American Heart Association's Quality of Care & Outcomes Research Scientific Sessions 2012.

Penn researchers identify possible new way to fight rare blood disorder

A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that new pre-clinical data using proprietary rxRNA™ compounds was presented at the Keystone Symposia's RNA Silencing: Mechanism, Biology and Application held January 14-19 in Keystone, Colorado.

Read more Medical News

› Verified 3 days ago